PDTX Model for TME Research
Relying on the tumor microenvironment center technology platform, Alfa Oncology provides customized services for (patient-derived tumor xenograft) PDTX models for TME studies, helping researchers successfully achieve their research goals.
Patient derived xenograft (PDX) is a tumor model established by transplanting fresh tumor tissue from patients directly into immunodeficient mice. The PDX model maintains the heterogeneity of the tumor without any artificial culture, so its biological characteristics are more complete and more similar to the clinic, which is the most excellent animal model of tumor at this stage. Patient derived xenograft (PDX), as a classical in vivo experimental method, is in great demand in oncology research and antitumor drug development. In particular, they are advantageous in combination with other methods to explore or validate therapeutic approaches targeting the tumor microenvironment.
PDX models are considered the most predictive preclinical models and provide an accurate way to assess drug efficacy before entering the clinic. Alfa Oncology has established a variety of effective patient-derived xenograft (PDX) models, providing you with more than 3,000 PDX models, supporting the translation of preclinical tumor and microenvironment research into more than 30 human cancer types, including rare adaptations disease and highly specific analysis targets. Alfa Oncology will assist you with targeted therapy research in tumors and microenvironments.
- Alfa Oncology can provide a variety of PDX models for a variety of human cancer types. Please consult us for specific PDX models, human cancer types such as: acute myeloid leukemia, adrenal cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer, gallbladder cancer, stomach cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, mesothelioma, mixed mullerian cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, testicular cancer, thyroid cancer, uterine cancer.
- Animal: mouse
- Inoculation site: subcutaneous or in situ.
Note: Our services list is constantly being updated and improved, please contact us by email for more up-to-date and relevant information.
- PDX better preserves the tumor mesenchymal and stem cell components during transplantation, allowing for a tumor growth microenvironment that more closely resembles the actual situation.
- The PDX model mimics human tumor biology and allows for natural cancer progression. Moreover, the specimens used for transplantation are directly derived from human tumor tissues and are not cultured in vitro, which stably preserves the genetic characteristics, histological and phenotypic features of the tumor, i.e. tumor heterogeneity.
- PDX can be used to screen for chemotherapeutic drug sensitivity or resistance markers, and its test results have good clinical predictability.
- Provide a large number of specimens for tumor sample preservation and passaging.
- The main source of original tumors for PDX models is surgical resection, which is difficult to model and cannot be obtained repeatedly. The tumor microenvironment will be gradually replaced by mouse extracellular matrix as the number of passages increases, so there is a limit to the number of passages, usually no more than 10 generations of samples.
Alfa Oncology is dedicated to supporting scientists in making groundbreaking scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. We have established the tumor microenvironment center technology platform with high performance scientific instruments and high value solutions to ensure high quality services that enable scientists to explore the mysteries of life at the tumor microenvironment level. Please let us know your project requirements and we will provide you with a comprehensive service from solution to report. If you have any questions, please feel free to contact us.